ADKAngela DM KashubaBScPhm, PharmD, DABCP, FCPSlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Target Concentrations - Angela Kashuba, PharmDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016ViiV - Cabotegravir - Bill Spreen, PharmDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016FDA Perspective on "oral run-in" phase - Dr. Yodit BelewView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Virologic and Immunologic Responses to Raltegravir and Dolutegravir in GALT of HIV+ Men and Women - Michael Weber, PharmDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Pharmacogenetics of Efavirenz Discontinuation for Central Nervous System Symptoms at a Southeastern United States Clinic May Differ by Race - Paul Leger, MD, MPHView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Intracellular Metabolism of Tenofovir Alafenamide in Cervical and Vaginal Epithelial Cells - Mackenzie Cottrell, PharmDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Evaluation of Drug-Drug Interaction Between Sofosbuvir/Velpatasvir and Rifaximin in HCV-Infected Subjects with Moderate Hepatic Impairment - Erik MogalianView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Cumulative tenofovir exposure is associated with decreased BMD in young and old HIV-infected adults on tenofovir based regimens - Sharon Seifert, PhramDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016The FDA Perspective on Hepatitis C Drug Resistance - Patrick Harrington, PHDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Effect of daclatasvir/asunaprevir/beclabuvir in fixed-dose combination on the pharmacokinetics of CYP450/transporter substrates in healthy subjects- Dr. Tushar GarimellaView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Effect of Renal Impairment on Drugs Primarily Eliminated by Metabolism or Biliary Excretion: Review of Data from HCV DAA Drugs and Literature - Dr. Tushar GarimellaView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Other Viruses: using Wolbachia to interrupt transmission of viral infections such as Dengue, Chikungunya and Zika - Steven Kern, PhDView Slideset
